Skip to main content

In Brief This Week: Alere, Interpace Diagnostics, Genetic Technologies, and More

NEW YORK (360Dx) – Alere this week informed the New York Stock Exchange in writing of its intention to voluntarily delist its Series B convertible perpetual preferred stock from the exchange. The delisting is dependent on the successful completion of Abbott’s $5.3 billion acquisition of Alere. 

Alere also declared a cash dividend of $3 per share on its Series B convertible perpetual preferred stock, payable on Oct. 16 to shareholders of record at the close of business on Oct. 2.


Interpace Diagnostics Group said that on Sept. 18 it received a letter from Nasdaq stating that it has regained compliance with a listing rule that requires three audit committee members on its board of directors. An audit committee has responsibility for oversight of financial reporting and disclosure.

In April, Interpace said that it had regained compliance with a Nasdaq listing requirement calling for at least $2.5 million in stockholder equity.


Genetic Technologies is moving to the web to sell its nonhereditary breast cancer testing service. The firm, which earlier in the year announced it was switching to a direct self-pay model from a traditional insurance reimbursement-based payment system, said this week it is moving its commercial program to an e-commerce-based model.

Customers will now be able to access the firm's Consumer Initiated Testing platform via the website of Genetic Technologies' US subsidiary, Phenogen Sciences. CIT provides testing with guidance from a remote physician. The company offers its Brevagenplus test for $349.


Agilent Technologies this week announced that a quarterly dividend of $.132 per share of common stock will be paid on Oct. 25 to all shareholders of record as of the close of business on Oct. 3.


N-of-One said that it is incorporating recent Association for Molecular Pathology guidelines on reporting somatic cancer variants with enhanced levels of evidence into the firm's existing curation and reporting solutions. N-of-One uses its proprietary knowledge base and its team of oncologists and scientists to integrate molecular data from multiple tests. Customers can use its solutions to standardize and accelerate genomic clinical interpretation and molecular decision support, the firm said.


HTG Molecular Diagnostics has received continued ISO 13485 certification for its quality management system. The certification was issued by a registrar accredited under the Canadian Medical Device Conformity Assessment System, which is required by regulators in Canada to market in vitro diagnostic products in that country.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.